Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review

OBJECTIVE: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelton, William Paul, Castagno, Jacqueline, Cardenas-Goicoechea, Joel, Daily, Karen, Yeung, Anamaria, Markham, Merry Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989046/
https://www.ncbi.nlm.nih.gov/pubmed/29887734
http://dx.doi.org/10.1177/1179554918779587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989046/
https://www.ncbi.nlm.nih.gov/pubmed/29887734
http://dx.doi.org/10.1177/1179554918779587

Ejemplares similares